The Diagnosis of Chronic Pancreatitis
Unknown statusNCT01059669
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
To develop a new standardized multimodal diagnostic approach to CP considering: WP 1: Fat in faeces and functional testing; the combination of tests has to be easy to practice, should take as little time as possible and discomfort for the patient has to be minimized WP 2: Advanced ultrasonography and imaging modalities. The focus is on validating standard parenchymal, contrast enhanced and functional ultrasound compared to a modern imaging standard. (CT, EUS, MRI) To evaluate the reliability and feasibility of these novel methods in healthy volunteers; AND To compare findings in known severe CP patients and different stages of pancreatic insufficiency in patients with CP.
Study details
- Official title
- A Multimodal Approach to Diagnose Patients With Chronic Pancreatitis
- Conditions
- Interventions
- Other: diagnostic test
- Sponsor
- Haukeland University Hospital
- Collaborators
- University of Bergen
- Start date
- 2009-08
- Primary completion
- 2020-08
- Sex
- All
- Age range
- from 16 Years to 90 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- Norway
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * The patients will be included from the Department of Medicine at Haukeland University Hospital in Norway. The Marseille-Rome diagnostic criteria will be used. Patients will be scored according to the Layer score. The symptoms should be unrelated to other systemic diseases. Exclusion Criteria: * Personality disturbances and alcohol consumption 24 hours prior to the study. Any other diseases and drugs associated with malabsorption; pregnancy or lactating women; heart disease or allergy against MR or ultrasound contrast agents.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01059669